Relay Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Relay Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RLAY
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001812364
Board of directors
- Since 2023
-
Claire Mazumdar · DirectorSince 2025
-
Douglas S. Ingram · DirectorSince 2023
- Since 2025
-
Jami Rubin · DirectorSince 2023
-
Laura Shawver · DirectorSince 2023
-
Linda A. Hill · DirectorSince 2023
-
Lonnel Coats · DirectorSince 2025
-
Mark Murcko · DirectorSince 2023
-
Sanjiv Patel · Director · President and CEOSince 2023
-
Sekar Kathiresan · DirectorSince 2023
Chief executives
Sanjiv Patel
· President and CEO
Dates unknown
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.2%
-
83.6%
Board connections
7 of this board's directors also sit on 14 other boards.
- via Laura Shawver
- via Douglas S. Ingram
- via Claire Mazumdar
- via Habib J. Dable
- via Lonnel Coats
- via Sekar Kathiresan
- via Alexis Borisy
- via Alexis Borisy
- via Habib J. Dable
- via Alexis Borisy
- via Douglas S. Ingram
- via Habib J. Dable
- via Alexis Borisy
- via Habib J. Dable
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $129,017,392
- 38 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Bergstrom Donald A Officer (President, R&D) | Open-market sale | −8,530 | $18.97 | $161,814 |
| Sep 8, 2026 | Catinazzo Thomas Officer (Chief Financial Officer) | Open-market sale | −17,717 | $18.94 | $335,560 |
| Sep 8, 2026 | Sanjiv Patel Director, Officer (President and CEO) | Open-market sale | −48,199 | $18.94 | $912,889 |
| Aug 26, 2026 | Rahmer Peter Officer (See remarks) | Open-market sale | −4,508 | $20.03 | $90,295 |
| Aug 25, 2026 | SVF Pauling (Cayman) Ltd 10% owner | Open-market sale | −6,000,000 | $19.40 | $116,400,000 |
| Aug 17, 2026 | Sanjiv Patel Director, Officer (President and CEO) | Open-market sale | −48,199 | $20.33 | $979,886 |
| Aug 14, 2026 | Catinazzo Thomas Officer (Chief Financial Officer) | Open-market sale | −17,717 | $19.74 | $349,734 |
| Jul 28, 2026 | Bergstrom Donald A Officer (President, R&D) | Open-market sale | −2,237 | $18.61 | $41,631 |
| Jul 28, 2026 | Catinazzo Thomas Officer (Chief Financial Officer) | Open-market sale | −1,459 | $18.61 | $27,152 |
| Jul 28, 2026 | Rahmer Peter Officer (See remarks) | Open-market sale | −748 | $18.61 | $13,920 |
| Jul 7, 2026 | Sanjiv Patel Director, Officer (President and CEO) | Open-market sale | −48,199 | $19.58 | $943,736 |
| Jul 6, 2026 | Bergstrom Donald A Officer (President, R&D) | Open-market sale | −8,660 | $18.71 | $162,029 |
| Jul 6, 2026 | Catinazzo Thomas Officer (Chief Financial Officer) | Open-market sale | −17,717 | $18.69 | $331,131 |
| Jun 30, 2026 | Rahmer Peter Officer (See remarks) | Open-market sale | −50,000 | $19.09 | $954,500 |
| Jun 30, 2026 | Sanjiv Patel Director, Officer (President and CEO) | Grant or award | +3,056 | $6.95 | $21,239 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.